Does Methylergonovine Interact with Ranitidine?
CDI records a moderate classification for Methylergonovine and Ranitidine. The stored summary is: Weak CYP 3A4 inhibitor; should be administered with caution. The mechanism involves cyp 3a4 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Ranitidine Class
- Histamine-2 Receptor Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP 3A4 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Methylergonovine and your doctor is considering prescribing Ranitidine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider